EGFR and non-small cell lung carcinoma: Most of the clinical trials (Urata et al., 2016; Yang et al., 2017; He et al., 2021) showed that there were no differences in the therapeutic effects between gefitinib and erlotinib for EGFR-mutated NSCLC patients, complicating the choice of optimum drugs.